5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC
First-line pembrolizumab plus chemotherapy demonstrates long-term effectiveness for nonsquamous and squamous advanced/metastatic NSCLC, with 5-year OS rates in real-world settings that are consistent across PD-L1 expression strata with 5-year outcomes from the pivotal clinical trials.
Authors
- Stephen V. Liu (ORCID: https://orcid.org/0000-0002-4852-3914)
- Riddhi A. Babel (ORCID: https://orcid.org/0000-0002-3543-7160)
- Yu-Han Kao (ORCID: https://orcid.org/0000-0003-2416-4395)
- Vamsidhar Velcheti (ORCID: https://orcid.org/0000-0002-6589-0759)
- Diana Chirovsky (ORCID: https://orcid.org/0000-0003-1641-1990)
- Azadeh Namakydoust (ORCID: https://orcid.org/0000-0002-5252-5648)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Georgetown University (US)
- Georgetown University Medical Center (US)
- NYU Langone Health (US)
Publication Details
- Journal
- Immunotherapy
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1080/1750743x.2025.2569856
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05